Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31465140 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL17725159 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL8024923 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL5308716 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL7650398 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL14286742 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL15935504 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL7873800 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL13169264 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 | |
| SCHEMBL27050968 | 0.94 | TSHR (0.39) | ZDHHC20TSHRSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545915-B2 | Anti-ADAM33 oligonucleotides and related methods | UNIVERSITY OF MASSACHUSETTS (US) | 2026-02-10 | — | — | US | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-20230095566-A1 | ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS | UNIVERSITY OF SOUTHAMPTON (GB) | 2023-03-30 | — | — | US | disclosed |
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017155923-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017106710-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | ZDHHC20 2347/4885TSHR 3640/4885SPHK1 1334/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | ZDHHC20 4014/4885TSHR 3619/4885SPHK1 1071/4885 |
| US-12545915-B2 | Anti-ADAM33 oligonucleotides and related methods | ADAM33, RBM39, RNASE1 | ZDHHC20 2025/4885TSHR 2166/4885SPHK1 2882/4885 |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ADA, CDA | ZDHHC20 3048/4885TSHR 4554/4885SPHK1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.